.

Changes in sphingomyelinases, ceramide, Bax, Bcl2, and caspase-3 during and after experimental status epilepticus

LAUR Repository

Show simple item record

dc.contributor.author Abi-Habib, Ralph
dc.contributor.author Mikati, Mohamad A.
dc.contributor.author Zeineh, Michel
dc.contributor.author El Hokayem, Jimmy
dc.contributor.author Rahmeh, Amal
dc.contributor.author El Sabban, Marwan
dc.contributor.author Usta, Julnar
dc.contributor.author Dbaibo, Ghassan
dc.date.accessioned 2015-11-30T09:08:50Z
dc.date.available 2015-11-30T09:08:50Z
dc.date.copyright 2008
dc.date.issued 2015-11-30
dc.identifier.issn 0920-1211 en_US
dc.identifier.uri http://hdl.handle.net/10725/2733
dc.description.abstract Status epilepticus (SE) induces a number of events leading to programmed cell death (PCD). The aim of our work is to study the time sequence of activation of different factors in experimental SE (intraperitoneal kainic acid (KA) model). We studied ceramide, a known mediator of apoptosis in multiple models, sphingomyelinases (SMases), enzymes that break down sphingomyelin and increase ceramide thus leading to apoptosis in many models, Bcl2, Bax, and caspase-3. SE induced a sustained ceramide increase starting 2 h after kainic acid injection followed by an increase in Bax protein at 6 and 12 h, and the appearance of caspase-3-activated fragment (caspase-3a) immunostaining and TUNEL positivity at 12 h. Status epilepticus also induced an increase in acidic and neutral sphingomyelinases that preceded (acidic sphingomyelinase) and parallelled (acidic and neutral sphingomyelinase) the increases in ceramide. These data suggest that, in this model, Bax is activated early in the process and that its increase is sustained till 12 h after kainic acid injection which is the time of first appearance of caspase-3 activation and TUNEL positivity, and that SMases contribute to increases in ceramide levels during and after status epilepticus. en_US
dc.language.iso en en_US
dc.title Changes in sphingomyelinases, ceramide, Bax, Bcl2, and caspase-3 during and after experimental status epilepticus en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SAS en_US
dc.author.idnumber 200901419 en_US
dc.author.woa N/A en_US
dc.author.department Natural Sciences en_US
dc.description.embargo N/A en_US
dc.relation.journal Epilepsy Research en_US
dc.journal.volume 81 en_US
dc.journal.issue 2-3 en_US
dc.article.pages 161-166 en_US
dc.keywords Status epilepticus en_US
dc.keywords Ceramide en_US
dc.keywords Kainic acid en_US
dc.keywords Bax en_US
dc.keywords Caspase-3 en_US
dc.keywords Sphingomyelinase en_US
dc.identifier.doi http://dx.doi.org/10.1016/j.eplepsyres.2008.05.009 en_US
dc.identifier.ctation Mikati, M. A., Zeinieh, M., Habib, R. A., El Hokayem, J., Rahmeh, A., El Sabban, M., ... & Dbaibo, G. (2008). Changes in sphingomyelinases, ceramide, Bax, Bcl 2, and caspase-3 during and after experimental status epilepticus. Epilepsy research, 81(2), 161-166. en_US
dc.author.email ralph.abihabib@lau.edu.lb
dc.identifier.url http://www.sciencedirect.com/science/article/pii/S0920121108001393


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR


Advanced Search

Browse

My Account